Clinical Trials Directory

Trials / Available

AvailableNCT05222412

Managed Access Programs for LNP023, Iptacopan

Status
Available
Phase
—
Study type
Expanded Access
Enrollment
—
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan

Detailed description

* CLNP023B12004M - Available - Managed Access Program (MAP) Cohort Treatment Plan CLNP023B12004M to Provide Access to Iptacopan (LNP023) for Complement 3 Glomerulopathy in Native and Transplanted Kidneys. * CLNP023N12001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CLNP023N12001M to provide access to Iptacopan for patients with paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

Interventions

TypeNameDescription
DRUGIptacopanPatients receive Iptacopan

Timeline

First posted
2022-02-03
Last updated
2025-12-05

Source: ClinicalTrials.gov record NCT05222412. Inclusion in this directory is not an endorsement.